Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Smoldering myeloma treatment landscape & MRD negativity

The best chance to acheive measurable residual disease (MRD) negativity is to treat in the smoldering stage of multiple myeloma (MM), as discussed here by Annemiek Broyl, MD, PhD, from Erasmus Medical Center and University, Rotterdam, Netherlands. Dr Broyl covers what the data indicate for the treatment of this population. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.